Development
Can-Fite's namodenoson boosts gemcitabine potency in pancreatic cancer preclinical models
New preclinical data from Can-Fite BioPharma Ltd. (NYSE American: CANF) show that namodenoson, an oral A3 adenosine receptor (A3AR) agonist, enhances the...
AstraZeneca drops Phase III volrustomig trial after pembrolizumab challenge fails
AstraZeneca (LSE/STO/NYSE: AZN) is discontinuing the eVOLVE-Lung02 Phase III trial after an Independent Data Monitoring Committee (IDMC) concluded that...
argenx's Vyvgart Hytrulo delivers first Phase III success in IMNM
Efgartigimod alfa and hyaluronidase-qvfc met the primary endpoint of a Phase III trial in autoimmune myositis, delivering the first statistically...
Tagrisso plus Orpathys extends OS in MET-resistant EGFR-mutated lung cancer
The SAFFRON Phase III trial has delivered the first global Phase III evidence that a targeted oral combination can improve both progression-free and overall...
Voyager registers first-in-human trial of tau-silencing gene therapy VY1706 in Alzheimer’s
Voyager Therapeutics (Nasdaq: VYGR) has registered a Phase I VY1706 clinical trial in early Alzheimer's disease, marking the first time an adeno-associated...
Fate takes off-the-shelf CAR T into potentially registrational lupus nephritis trial
Fate Therapeutics (Nasdaq: FATE) has dosed the first patient in RECLAIM-LN, its Phase II potentially registrational trial of FT819, an off-the-shelf...
PhenoNet revives inhaled cromolyn for Phase III Alzheimer’s test
The FDA's clearance of a Phase III trial for an inhaled reformulation of a decades-old anti-allergy compound in Alzheimer's disease puts a privately held...
JW sets up epaminurad partnering push with Phase III gout win
A Phase III trial of epaminurad, a selective oral uricosuric agent for gout, has met its primary endpoint and demonstrated statistical superiority over an...
CRISPR Therapeutics takes one-shot gene editing into hypertension
CRISPR Therapeutics AG (Nasdaq: CRSP) has initiated a first-in-human clinical trial of CTX340, an in vivo gene editing therapy designed to permanently...
Photys and Polymed put oral IRAK4 PROTAC degrader into first-in-human
Waltham, Massachusetts-based Photys Therapeutics and China-based Polymed Biopharmaceuticals have dosed the first healthy volunteers in a Phase I trial of...
Patient groups raise alarm over Vykat XR use after seven deaths reported
Three Prader-Willi syndrome (PWS) patient organizations have issued a joint safety statement on diazoxide choline (Vykat XR), the first and only...
Regeneron quietly takes SF3B1-mutant therapy into first-in-human trial
Regeneron Pharmaceuticals (Nasdaq: REGN) has registered a first-in-human clinical trial of REGN17235, an investigational agent targeting clonal...
Zipalertinib Phase III win sets up first-line Rybrevant challenge
Taiho Oncology, Japan-based Taiho Pharmaceutical Co., Ltd., and Cambridge, Massachusetts-based Cullinan Therapeutics (Nasdaq: CGEM) announced that...
Simcere's pan-RAS inhibitor SIM0532 entering Phase I study
China-based Simcere Zaiming Pharmaceutical Co., Ltd., the oncology subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096), has initiated a...
Definium's LSD formulation scores second Phase III win in GAD
New York-based Definium Therapeutics (Nasdaq: DFTX) reported positive topline results from the Phase III Voyage study of lysergide orally disintegrating...
The AllSci Brief
Free, systematic R&D and deal news. Daily.